Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663648 | 0.91 | ESR1 (0.53) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL1664645 | 0.87 | ESR1 (0.49) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL1663630 | 0.79 | ESR1 (0.57) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL1664336 | 0.79 | ESR1 (0.60) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL1663398 | 0.79 | TRPV1 (0.72) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL1664004 | 0.78 | ESR1 (0.84) | ESR1TRPV1SMN1; SMN2MIFKMT2A | |
| SCHEMBL1665830 | 0.78 | TRPV1 (0.61) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL10446396 | 0.78 | SMN1; SMN2 (0.43) | ESR1SMN1; SMN2PDE10AKMT2AALDH1A1 | |
| SCHEMBL1663703 | 0.78 | ESR1 (0.52) | ESR1TRPV1ESR2SMN1; SMN2MIF | |
| SCHEMBL1666292 | 0.77 | TRPV1 (0.60) | ESR1TRPV1ESR2SMN1; SMN2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| CN-101356160-A | Trisubstituted quinazolinone derivatives as vanilloid antagonists | JANSSEN PHARMACEUTICA NV (CH) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | ESR1 1321/4885TRPV1 1/4885ESR2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.